What if there were a stent that could promote natural remodeling of an injured artery after angioplasty, and then just disappear? "Just three years ago bioresorbable stents seemed to be more of a nice to have than a need to have.  After all, drug-eluting stents (DES) were seen as the answer to restenosis and showed very minimal risks to patient safety. Johnson & Johnson and Boston Scientific had the clear lead in introducing Cypher and Taxus, respectively, to the interventional community, with Medtronic, Guidant, and Abbott Laboratories bringing up the rear. Then in September 2006 at the World Congress of Cardiology meeting...DES were linked to a four-letter word delivering a new danger corporate executives once again began asking a question they thought they had answered: why deploy a permanent implant on a short-term mission of clearing a coronary artery?" (Source: 'Bioabsorbable Stents', Start-Up, January 2007)  In part two of “Vanishing Stents”, we again consider Paris-based ARTERIAL REMODELING TECHNOLOGIES ("ART").  ART's stent is designed to provide the requisite initial acute mechanical scaffolding, but, as it dismantles due to bioresorbability, the possibility of arterial remodeling returns to the artery.  Our expert is Antoine Lafont, MD, PhD, Professor of Medicine at the University of Paris; Head of Interventional Cardiology at Georges Pompidou Hospital in Paris; and, Chairman of the Interventional Cardiology Group of the European Society of Cardiology (ESC). Dr. Lafont is a co-founder of ART.